Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2012 Oct;1(5):e005272.
doi: 10.1161/JAHA.112.005272. Epub 2012 Oct 25.

Can long-term results following balloon angioplasty be the "crystal ball" to predict outcome following bioresorbable vascular scaffolds?

Antonio Colombo, Azeem Latib
Editorial

Can long-term results following balloon angioplasty be the "crystal ball" to predict outcome following bioresorbable vascular scaffolds?

Antonio Colombo et al. J Am Heart Assoc. 2012 Oct.
No abstract available

Keywords: bioresorbable vascular scaffold; coronary stent; drug-eluting stent; editorials; late stent thrombosis; stent thrombosis.

PubMed Disclaimer

Comment on

References

    1. Yamaji K, Kimura T, Morimoto T, Nakagawa Y, Inoue K, Kuramitsu S, Soga Y, Arita T, Shirai S, Ando K, Kondo K, Sakai K, Iwabuchi M, Yokoi H, Nosaka H, Nobuyoshi M. Very long-term (15-23 years) outcomes of successful balloon angioplasty compared with bare metal coronary stenting. J Am Heart Assoc. 2012;1:e004085.doi: - DOI - PMC - PubMed
    1. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet. 2008;371:899-907. - PubMed
    1. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hebert K, Veldhof S, Webster M, Thuesen L, Dudek D. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910. - PubMed
    1. Serruys PW, Onuma Y, Ormiston JA, de Bruyne B, Regar E, Dudek D, Thuesen L, Smits PC, Chevalier B, McClean D, Koolen J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Miquel-Hebert K, Rapoza R, Garcia-Garcia HM. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes. Circulation. 2010;122:2301-2312. - PubMed
    1. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, de Bruyne B, Thuesen L, McClean D, van Geuns R-J, Windecker S, Whitbourn R, Meredith I, Dorange C, Veldhof S, Hebert KM, Sudhir K, Garcia-Garcia HM, Ormiston JA. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis. J Am Coll Cardiol. 2011;58:1578-1588. - PubMed